{"database":"bioimages","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Bernhard Ellinger"],"species":["Homo sapiens"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-BIAD29"],"repository":["bioimages"],"additional_accession":["http://idr.openmicroscopy.org/webclient/?show=screen-2603"],"figure_sub":["Organization","Screen A","Protocol","Screen B"],"pubmed_authors":["Bernhard Ellinger"]},"is_claimable":false,"name":"SARS-COV-2 drug repurposing - Caco2 cell line","description":"To identify possible candidates for progression towards clinical studies against SARS-CoV-2, we screened a well-defined collection of 5632 compounds including 3488 compounds which have undergone clinical investigations (marketed drugs, phases 1 -3, and withdrawn) across 600 indications. Compounds were screened for their inhibition of viral induced cytotoxicity using the human epithelial colorectal adenocarcinoma cell line Caco-2 and a SARS-CoV-2 isolate. The primary screen of 5632 compounds gave 271 hits. A total of 64 compounds with IC50 <20 μM were identified, including 19 compounds with IC50 < 1 μM. Of this confirmed hit population, 90% have not yet been previously reported as active against SARS-CoV-2 in-vitro cell assays. Some 37 of the actives are launched drugs, 19 are in phases 1-3","dates":{"release":"2020-10-08T00:00:00Z","modification":"2023-08-21T07:40:51.803Z","creation":"2020-10-02T11:24:10Z"},"accession":"S-BIAD29","cross_references":{}}